Arkolith/Insider Trading/ANTX/Form 4

Easom Eric

Chief Executive Officer, DirectorAN2 Therapeutics, Inc. (ANTX) · full profile →Form 4 · filed Mar 23, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
0 non-derivative · 6 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 19, 2026Grant(A)268K——268K
Mar 19, 2026Disposed to issuer(D)225K——0
Mar 19, 2026Grant(A)225K——225K
Mar 19, 2026Disposed to issuer(D)250K——0
Mar 19, 2026Disposed to issuer(D)268K——0
Mar 19, 2026Grant(A)250K——250K

Transaction Codes

A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-120192) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML